ACIU Earnings Date: Nov 3, 2026 (Estimated) — AC Immune S.A.
NASDAQ · Healthcare · Biotechnology
Updated
When is ACIU's next earnings date?
AC Immune S.A. (ACIU) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.22 on revenue of $328,683.
How did ACIU do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), AC Immune S.A. posted EPS of $0.03 versus the -$0.10 estimate, a beat of 111.4%. Revenue was $19.1M against a $34.1M estimate. The stock's 1-day post-earnings move was +0.9%.
How much does ACIU stock move after earnings?
ACIU beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.1% (up or down) in the day after earnings.
About AC Immune S.A.
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.10 | 0.03 | +111.36% | $19.1M | ✅ Beat | +0.88% | +11.89% | +25.11% |
| 2026-04-30 | Q1 2026 | -0.20 | -0.19 | +5.00% | $1.4M | ✅ Beat | +3.41% | +1.37% | -9.21% |
| 2026-03-13 | Q4 2025 | -0.19 | -0.17 | +7.89% | $422,914 | ✅ Beat | +0.50% | -1.67% | +10.00% |
| 2025-11-04 | Q3 2025 | -0.22 | -0.20 | +9.09% | $1.2M | ✅ Beat | +3.77% | +5.35% | -10.38% |
| 2025-08-05 | Q2 2025 | -0.20 | -0.25 | -25.00% | $1.5M | ❌ Miss | +11.62% | -5.69% | +2.96% |
| 2025-04-30 | Q1 2025 | -0.21 | -0.21 | +0.00% | $1.1M | ➖ Inline | +1.76% | -4.71% | -0.29% |
| 2025-03-13 | Q4 2024 | -0.19 | -0.18 | +5.26% | $1.3M | ✅ Beat | -0.86% | -4.31% | -36.21% |
| 2024-11-05 | Q3 2024 | -0.23 | 0.06 | +126.09% | $29.4M | ✅ Beat | +10.20% | +7.82% | +8.84% |
Showing last 8 quarters.